SharePoint

    Frequently Asked Questions for applicants to Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs

    Following find answers to frequently asked questions for applicants to Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21) (PAR-17-474), released in September 2017.

    Note that the funding announcement expired on December 12, 2017. Please note that the FOA was issued with limited due dates to accommodate the transition to FORMS-E application packages. The FOA will be reissued for additional due dates after January 25, 2018.

    Important to note

    Scientific:

    • Review the types of acceptable research topics under Section 1- Objectives
    • Review the guidelines for what is encompassed under interventions and under health outcomes in Section 1
    • Follow guidelines provided in Section IV.2 under PHS 398 Research Plan
    • Discuss briefly strategies for research capacity strengthening at the LMIC institution into the proposed research program

    In summary, the following parts in the application should be identifiable - identify the population to work with and the stigma relevant to that population for which an intervention to reduce that stigma is being researched. Demonstrate that the use of that intervention has the stigma reducing capability and leads to a better health outcome (as defined in the RFA). Thus, the population, the type of stigma, intervention and health outcomes are strung together and reviewers must be able to identify them. Validating methods or developing new methods that could more accurately measure stigma reduction resulting in better health but must be linked to a stigma reduction intervention being contemplated.

    Administrative:

    • This FOA will be reissued for additional due date(s) on or after January 25, 2018 to accommodate the new clinical trials guidelines and transition from FORMS-D to FORMS-E.
    • Applications proposing studies that do not address a stigma reduction intervention strategy linked to measurement of a beneficial health outcome would not be supported under this FOA.
    • Applications proposing refinements to or validation of stigma measurement tools should make sure to link to health outcomes as a result of the reduction in stigma.
    • Non-U.S. based High Income Country investigators are not eligible as PD/PIs but may be included as consultants, especially if they present special opportunities for furthering research programs. That includes cannot be a Multiple PI team member.
    • At least one LMIC researcher and at least one U.S. researcher must be identified as key personnel.
    • Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
    • Revisions/Resubmissions do not apply to this FOA as all applications will be new.
    • Allowed Indirect Costa: PAR 17-474 will use the activity code, R21 to fund/award successful applications. The R21 mechanism is a Research Project Grant (RPG) and as such the 8% will not apply. Applicants will use their current negotiated facilities and administrative (F&A) rate applied to their modified direct cost.
    • Subcontract indirect cost are added to the total direct cost but are not used in the calculation for determining the direct “capped” cost, $125,000.

    Updated December 2017

    Footer